/ /

  • linkedin
  • Increase Font
  • Sharebar

    FDA grants priority review to aflibercept for diabetic retinopathy in patients with DME

    Terrytown, NYThe FDA has accepted for priority review Regeneron Pharmaceuticals’ supplemental biologics license application for aflibercept (Eylea) injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME).

    Under the Prescription Drug User Fee Act, the goal for a priority review is 6 months, for a target action date of March 30, 2015.

    More in this issue: How femtosecond laser-assisted cataract surgery helps in challenging cases

    In September, the FDA granted the injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with DME. The FDA created the Breakthrough Therapy designation to expedite the development and review of drugs for serious or life-threatening conditions.

    A Breakthrough Therapy drug must show preliminary clinical evidence of a substantial improvement on a clinically significant endpoint over available therapies, or over placebo if there is no available therapy.

    "Diabetic retinopathy coupled with DME is a significant threat to vision for people with diabetes," said George D. Yancopoulos, MD, PhD, chief scientific officer of Regeneron and president of Regeneron Laboratories. "Regeneron looks forward to working with the FDA to help address this significant treatment gap in a leading cause of blindness in working-age adults."

    Rose Schneider Krivich
    Rose is the content specialist for Medical Economics.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results